You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Moderna(MRNA.US)本港設分公司 正與政府洽商疫苗供應
阿思達克 02-16 11:11
美國藥廠莫德納(Moderna)(MRNA.US)行政總裁Stephane Bancel接受《南華早報》訪問時透露,公司將在香港開設分公司,支援香港及澳門的核糖核酸(mRNA)疫苗和療法,並主導研發亞洲所需的新疫苗。計劃初期招聘約1,000名員工,並將香港作爲通往中國的門戶,開拓亞洲醫療保健市場。 展望2022年,Bancel指公司將香港、臺灣、馬來西亞及新加坡視爲下一個自然增長因素。 此外,Bancel指公司正與香港當局討論在今年和2023年獲得批準並供應mRNA疫苗,但政府尚未作出決定。 他又預期,人類將不得不與新冠肺炎病毒共存,而公司正研發一款泛呼吸道疫苗,針對新冠肺炎、流感及呼吸道合胞病毒(RSV),料最快將於明年秋季能獲部分國家批準上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account